US 12,268,706 B2
Hyaluronic acid for relief of idiopathic ocular pain
Wolfgang Georg Konrad Müller-Lierheim, Munich (DE); and Gysbert-Botho Van Setten, Danderyd (SE)
Assigned to I.COM MEDICAL GMBH, Munich (DE)
Appl. No. 17/309,463
Filed by I.COM MEDICAL GMBH, Munich (DE)
PCT Filed Jan. 31, 2020, PCT No. PCT/IB2020/000053
§ 371(c)(1), (2) Date May 28, 2021,
PCT Pub. No. WO2020/157570, PCT Pub. Date Aug. 6, 2020.
Claims priority of provisional application 62/799,245, filed on Jan. 31, 2019.
Prior Publication US 2021/0369764 A1, Dec. 2, 2021
Int. Cl. A61K 31/728 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/728 (2013.01) [A61K 9/0048 (2013.01)] 16 Claims
 
1. A method for relieving idiopathic ocular pain, comprising topically administering an effective amount of a fluid comprising hyaluronic acid having an intrinsic viscosity of >2.5 m3/kg and a concentration of <0.2% w/v to the eye of a human or non-human animal subject, wherein the fluid is administered after onset of the idiopathic ocular pain and in the absence of detectable signs known to cause ocular pain.